THERAPY DOSSIER · th-5ab46fffa5d7

Human mesenchymal stem cells encapsulated in a biomimetic hydrogel scaffold, releasing CCL2 chemokine

Biologic · Human MSCs in a biomimetic hydrogel releasing CCL2; cell-biomaterial construct.

Evidence & regulatory context

Mechanism: Human MSCs in a biomimetic hydrogel releasing CCL2; cell-biomaterial construct.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29621597 ↗2018Reported benefit

Mesenchymal stem cells encapsulated into biomimetic hydrogel scaffold gradually release CCL2 chemokine in situ preserving cytoarchitecture and promoting functional recovery in spinal cord injury.

MouseSpinal cord injuryUnspecifiedC57BL/6 (per MeSH indexing)Local delivery to the lesioned spinal cord via hydrogel scaffold

Model: Traumatic spinal cord injury in rodent models

CCL2 secreted by MSCs and delivered from the hydrogel recruited macrophages and drove M2 conversion, prevented motor neuron degeneration in vitro and after spinal cord trauma in vivo, and significantly improved motor performance.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…